Diomune is a biotech company specialized in research and development of new immunology treatments oriented to human and animal health areas in infectious, inflammatory and autoimmune diseases.

Diomuner’s technological innovation lies in the discovery of a series of natural immunomodulatory compounds that act with a number of receptors involved in innate immunity and as a result of this interaction enhances the immune response against pathogens, prevents the development of inflammatory diseases and is enhanced the activity of vaccines that have lost effectiveness or lack of it directly.

Based on this discovery, the company focuses on the following development strategy:

Development of a drug to treat Canine Leishmaniosis.

Research and development of drugs for the treatment of human septicaemia.

Establishment of license agreements with other companies to use our products as vaccine adjuvants.